While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Compass Therapeutics will still submit tovecimig for approval despite the OS miss.

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

The Dallas-based developer is set to build an eight-building campus in Lauderdale County, that will see a total investment value of $10 billion. This figure includes the investment of IT equipment by ...

Compass Pathways may be the first to benefit from an accelerated approval process.

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...